Dear Visitor:

It is my pleasure to update you on some of the exciting developments at Biomay over the last few months.

As you may have seen in the press, we have recently completed a first in man trial with our innovative grass pollen allergy vaccine BM32. You can find the press release also in the news section. The study was performed in an excellent cooperation with the Vienna Challenge Chamber (VCC®) under the guidance of Prof. Friedrich Horak as Principle Investigator. We are gratified by the findings from this study, which showed a significant reduction of nasal and skin symptoms following an allergen challenge.

The treatment was safe and tolerated well. It is important to note that the patients only received three vaccine injections. Encouraged by these results, we have already embarked on the next stage of development for this product. Eleven leading allergy centers from Denmark to Slovenia have begun enrolling patients into the phase IIb trial; we expect to receive the results of this study in 2014.

We are fortunate that some of the most recognized opinion leaders in the field of allergy have agreed to work with us on this project. We will work diligently with them to make this innovative treatment available to allergy sufferers as quickly as possible.

On another note: Biomay is proud to have been selected to present at the prestigious Rodman & Renshaw 14th Global Annual Healthcare Conference as one of just four privately held companies. This selection underscores the importance of the development of novel allergy treatments. We have the opportunity to show our concepts and progress to thought leaders in the investment community at this event.

If you have questions and comments about us and our product, don't hesitate to contact us!

Best regards

Rainer Henning
Chief Executive Officer